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Abstract
Background: Patients with polyarticular-course juvenile idiopathic arthritis (pJIA), receiving disease-modifying anti-
rheumatic drugs with immunosuppressive effects, may be at increased risk of vaccine-preventable infections. This
substudy assessed protective antibody responses to diphtheria and tetanus vaccination given prior to study enrolment
in patients with pJIA.
Findings: This was a substudy of a 24-month, single-arm, open-label, multicenter, Phase III trial (NCT01844518) of
subcutaneous abatacept in children with active pJIA (N = 219). Patients aged 2–5 years, with ≥2 continuous months of
weekly weight-tiered (10–< 25 kg [50 mg], 25–< 50 kg [87.5 mg]) subcutaneous abatacept treatment (with/without
methotrexate and/or low-dose corticosteroids), who received diphtheria/tetanus vaccine prior to enrolment, were
eligible. Protective antibody levels to diphtheria/tetanus (> 0.1 IU/mL), and safety, were assessed.
Overall, 29 patients were analyzed: 19 (65.5%), 1 (3.4%) and 9 (31.0%) patients had > 12, 6–12 and 2–< 6months of
abatacept exposure, respectively. All patients had protective antibody levels to tetanus and 26 (89.7%) patients had
protective antibody levels to diphtheria. Of the 3 patients without protective antibody levels to diphtheria, each had an
antibody level of 0.1 IU/mL, bordering the lower threshold of protection. Concomitant use of methotrexate and/or low-
dose corticosteroids had no evident effect on antibody levels. No unexpected adverse events, including cases of
diphtheria or tetanus, were reported during the 24-month period.
Conclusions: Patients aged 2–5 years with pJIA who received 2–24months of weekly subcutaneous abatacept, with or
without concomitant methotrexate and/or low-dose corticosteroids, maintained effective diphtheria and tetanus
vaccination protection without new safety signals.
Trial registration: ClinicalTrials.gov (NCT01844518); registered May 1, 2013; https://clinicaltrials.gov/ct2/show/NCT01
844518?term=NCT01844518&rank=1
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Findings
Introduction
Patients with polyarticular-course juvenile idiopathic arth-
ritis (pJIA) receiving disease-modifying antirheumatic drugs
(DMARDs) with immunosuppressive effects may be at
increased risk of vaccine-preventable infections such as
diphtheria and tetanus. The European League Against
Rheumatism recommendations for the vaccination of chil-
dren with rheumatic diseases endorse adherence to national
guidelines for very young, healthy children [1]. However,
due to ongoing maturation of the immune system in young
children [2, 3], immune responses to vaccination in this
population may be compromised by immunosuppressive
medications more so than in older children [4].
Abatacept, a selective T-cell co-stimulation modulator
[5], was effective and well-tolerated in children with pJIA
aged 2–17 years (subcutaneous [SC] formulation) [6], and
in children aged 6–17 years (intravenous [IV] formulation)
[7]. In healthy adults, a single 750-mg dose of IV abatacept
did not prevent induction of protective antibodies to tet-
anus toxoid or standard 23-valent pneumococcal vaccine
[8]. Adults with rheumatoid arthritis (RA) who received ≥3
months’ SC abatacept treatment (125mg/week with con-
comitant methotrexate [MTX] and/or low-dose corticoste-
roids) could mount an appropriate immune response to the
23-valent pneumococcal vaccine and 2011–2012 trivalent
seasonal influenza vaccine [9]. However, studies investigat-
ing the effects of abatacept on vaccination in very young
children with JIA are lacking. This substudy assessed pro-
tective antibody response to diphtheria and tetanus vaccin-
ation given prior to study enrolment in patients aged 2–5
years with pJIA.
Methods
Study design and patient population
This substudy of a 24-month, Phase III trial
(NCT01844518) of SC abatacept in patients (cohort 1: 173
patients aged 6–17 years; cohort 2: 46 patients aged 2–5
years) with active pJIA and inadequate response/intolerance
to ≥1 DMARD [6] was conducted across 48 centers world-
wide by members of the Paediatric Rheumatology Inter-
national Trials Organisation [10] and the Pediatric
Rheumatology Collaborative Study Group [11]. Patients re-
ceived weight-tiered weekly SC abatacept (10–< 25 kg [50
mg], 25–< 50 kg [87.5mg]) for 4months. JIA-American
College of Rheumatology criteria 30% improvement re-
sponders at Month 4 could receive treatment for another
20months. Stable doses of concomitant MTX (≤30mg/m2/
week) and low-dose oral corticosteroids (≤10mg/day or ≤
0.2mg/kg/day [whichever was less] prednisone equivalent)
were permitted if used at baseline. The concomitant use of
a tumour necrosis factor inhibitor (TNFi) was prohibited;
10/46 (22%) patients had prior TNFi treatment (adalimu-
mab, etanercept or tocilizumab) [6]. Patients from cohort 2,
with ≥2 continuous months of abatacept treatment, who re-
ceived diphtheria/tetanus vaccine prior to enrolment and
who were consented to participate by their legal guardians,
were included in this substudy. A 60-day washout period
was required for other biologics prior to the first dose of
abatacept; therefore, levels of other biologics would be non-
existent and should not influence the results of this
analysis.
Outcomes and analysis
A single blood sample was obtained to assess antibody
levels to tetanus and diphtheria. Assessment of blood anti-
body levels was performed by a central laboratory (ARUP
Laboratories, Salt Lake City, UT, USA) using quantitative
multiplex bead assays [12]. Protective antibody levels to
diphtheria and tetanus were defined as > 0.1 IU/mL by the
central laboratory, Centers for Disease Control and Preven-
tion (CDC) and World Health Organization (WHO) cri-
teria [12–15]. Immunogenicity of the pertussis component
of this vaccine was not studied, as there is no established
WHO-defined measure of protection against pertussis fol-
lowing immunization or natural infection [16] and the cen-
tral laboratory used WHO-defined protective antibody
levels for diphtheria and tetanus [13, 14]. Potential impact
of concomitant immunosuppressive medications (MTX
and/or low-dose corticosteroids [prednisone]) on diph-
theria and tetanus antibody levels was evaluated descrip-
tively by medication at the time of blood sample collection.
Patient demographics, antibody level data and safety were
analyzed descriptively.
Results
Patient disposition and baseline characteristics
Overall, 29/46 (63.0%) patients from cohort 2 participated
in this substudy. Baseline characteristics of the patients
who participated versus those who did not participate
were similar (Table 1). Among participants, 19 (65.5%), 1
(3.4%) and 9 (31.0%) had > 12, 6–12 and 2–< 6months of
abatacept exposure, respectively. All patients were vacci-
nated before abatacept initiation; one patient received a
single vaccination during the study after 3 months of aba-
tacept treatment.
Protective antibody assessment
Antibody assessment in individual patients is presented
in Table 2. All patients had protective antibody levels to
tetanus after ≥2 months of abatacept treatment and 26/
29 (89.7%) patients had protective antibody levels to
diphtheria. Of the remaining 3 patients (Table 2; patients
18, 20 and 24), each had a protective antibody level to
diphtheria of 0.1 IU/mL, which bordered the lower
threshold of protection [12, 14]. These 3 patients re-
ceived 4 injections (3 initial injections and one booster
shot) of combined diphtheria, hepatitis B, Haemophilus
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influenzae type b, pertussis, poliomyelitis and tetanus
vaccine or combined diphtheria, tetanus and pertussis
vaccine with 21–49months between last injection and
abatacept initiation and 24–79 months between last in-
jection and antibody assessment. No differences were
noted in types of vaccines received by, or in the vaccine
schedules of, patients who maintained protective anti-
body levels to diphtheria or the 3 patients with border-
line levels. Concomitant use of MTX and/or low-dose
corticosteroids had no evident effect on antibody levels:
19/20 (95.0%) patients receiving MTX and/or low-dose
corticosteroids maintained protective levels to diphtheria
and tetanus compared with 7/9 (77.8%) patients receiv-
ing no MTX or corticosteroids.
Safety
A safety summary of cohort 2 is presented in Table 3. Aba-
tacept safety profile was consistent between age cohorts [6].
Table 1 Baseline demographics and disease characteristics of patients who participated in the vaccination substudy and of those
who did not
Participated
n = 29
Did not participate
n = 17
Total cohort 2a
n = 46
Age at enrolment, years 4.2 (0.9) 3.8 (1.2) 4.1 (1.0)
Female, n (%) 16 (55.2) 12 (70.6) 28 (60.9)
Weight, kg 18.4 (3.6) 18.0 (3.5) 18.2 (3.5)
Weight categories, kg, n (%)
< 25 27 (93.1) 16 (94.1) 43 (93.5)
25–50 2 (6.9) 1 (5.9) 3 (6.5)
≥ 50 0 0 0
Race, n (%)
White 29 (100.0) 15 (88.2) 44 (95.7)
Black/African American 0 1 (5.9) 1 (2.2)
Other 0 1 (5.9) 1 (2.2)
Geographic region, n (%)
South America 4 (13.8) 4 (23.5) 8 (17.4)
Europe 25 (86.2) 11 (64.7) 36 (78.3)
Rest of world 0 2 (11.8) 2 (4.3)
Duration of JIA, years 0.8 (1.0) 0.8 (1.0) 0.8 (1.0)
JIA disease onset categories, n (%)
Polyarthritis RF− 18 (62.1) 12 (70.6) 29 (63.0)
Polyarthritis RF+ 0 2 (11.8) 3 (6.5)
Extended oligoarthritis 8 (27.6) 2 (11.8) 10 (21.7)
Psoriatic arthritis 3 (10.3) 1 (5.9) 4 (8.7)
No. of active joints 10.0 (6.4) 8.1 (5.2) 9.3 (6.0)
No. of joints with limitation of motion 9.6 (5.9) 7.1 (4.8) 8.7 (5.6)
CHAQ-DI score 1.0 (0.7) 1.2 (0.6) 1.1 (0.7)
Parent global assessment score 37.0 (22.9) 41.4 (26.0) 38.6 (23.9)
Physicians global assessment score 50.2 (16.1) 41.9 (20.4) 47.1 (18.0)
CRP, mg/dL 0.8 (1.4) 2.3 (3.4) 1.3 (2.4)
MTX dose ay Day 1, mg/m2/week n = 22
13.5 (4.5)
n = 14
12.0 (2.3)
n = 37
12.9 (3.8)
Prednisone dose at Day 1, mg/kg/day n = 3
0.2 (0.0)
n = 5
0.3 (0.2)
n = 8
0.2 (0.1)
Data are mean (SD) unless otherwise specified. Baseline is Day 1 of the study or the last measurement prior to short-term dose. Cohort 2 included all patients
aged 2–5 years. Minor differences between the data for total cohort 2 and those for the participated patients and patients who did not participate in the substudy
are due to the different dates of database lock (participated patients and patients who did not participate: July 2, 2018; total cohort 2: February 16, 2017)
aIncludes all patients who did or did not participate in the vaccination substudy
CHAQ-DI Childhood Health Assessment Questionnaire-Disability Index, CRP C-reactive protein, JIA juvenile idiopathic arthritis, MTX methotrexate, RF
rheumatoid factor
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Related serious adverse events (SAEs), SAEs and related
AEs were reported in a higher proportion of patients who
participated versus those who did not participate in this
substudy. Due to the relatively small sample size, these data
should be interpreted with caution. No cases of diphtheria
or tetanus, or symptoms suggestive of an untoward reaction
to the vaccine, were reported during the 24-month period.
Discussion
In this substudy of patients aged 2–5 years with pJIA and
prolonged exposure to SC abatacept, all patients main-
tained protective antibody levels to tetanus, and all but 3
to diphtheria following vaccination prior to study enrol-
ment. Addition of MTX and/or low-dose corticosteroid to
SC abatacept treatment did not appear to prevent the
maintenance of protective antibody levels in this popula-
tion. Immune system maturation takes place over the
early years of life [2, 3]; therefore, ensuring that very
young patients who are receiving immunosuppressive
medication can maintain protective antibody levels in re-
sponse to vaccination is important.
According to the CDC, a complete vaccine series leads to
development of protective antibody levels in nearly 100% of
healthy children for tetanus and 95% for diphtheria [15],
which corresponds to the findings of this study. In the sub-
studies of two trials that included adults with RA who re-
ceived ≥3months of treatment with abatacept, 74% of
patients achieved an immunological response to influenza
vaccination and 61% to standard 23-valent pneumococcal
polysaccharide vaccine [9], similar to the responses seen in
the general population [17, 18]. Importantly, in the present
trial, patients were vaccinated before abatacept treatment,
whereas in the aforementioned trials, vaccination was ad-
ministered to patients after treatment with abatacept.
Published research of vaccination in patients with JIA
receiving treatment with biologics is limited. Among 15
patients with JIA aged 6–17 years, neither low-dose MTX
nor etanercept caused statistically relevant differences in
protective antibody levels following measles, mumps and
rubella vaccination compared with untreated healthy con-
trols [19]. Similarly, among 27 patients with mean (stand-
ard deviation [SD]) age of 10.4 (5.6) years with systemic-
onset JIA who received tocilizumab for a mean (SD) of 1.9
(1.4) years and 17 healthy controls, efficacy of influenza
vaccination did not differ significantly between the groups
[20]. In addition, in a double-blind, randomized controlled
trial, anakinra treatment did not prevent the generation or
maintenance of protective antibody levels to standard 23-
valent pneumococcal vaccine after 12months in patients
with systemic-onset JIA and a mean (SD) age of 9.5 (5.2)
years [21]. In a study of the effects of TNFi treatment on
the immunogenicity of 7-valent conjugate pneumococcal
vaccine in patients with JIA aged 4–18 years, 87–100% of
patients generated protective antibody levels, depending
on vaccine serotype [22].
As shown in other studies evaluating vaccination in pa-
tients with JIA (reviewed in Groot N, et al. [4]), including a
large retrospective cross-sectional analysis [23], concomi-
tant treatment with MTX and/or low-dose corticosteroids
does not prevent the generation of protective antibody ti-
tres in patients with JIA. Patients receiving treatment with
corticosteroids may show lower seroconversion rates, but
they usually still reach protective antibody titres [24].
The limitations of this study should be considered. All
patients included in this study were of a similar back-
ground (100% white; 86% from Europe), which may limit
the generalizability of the findings. In addition, the sam-
ple size was relatively small and as the analysis was not a
classically designed vaccination study, where vaccination
is administered during the trial, it was not possible to
determine if the patients with borderline protective anti-
body titres ever had protective levels following vaccin-
ation, or the rate at which these titres decreased;
therefore, the data should be interpreted with caution.
Table 3 Safety summary for patients who participated in the vaccination substudy and for those who did not
Event Participated
n = 29
Did not participate
n = 17
Total cohort 2a
n = 46
Deaths 0 0 0
SAEs 4 (13.8)b 1 (5.9) 5 (10.9)
Related SAEsc 2 (6.9) 0 2 (4.3)
Discontinued due to SAEs 0 0 0
AEs 29 (100.0) 15 (88.2) 44 (95.7)
Related AEs 23 (79.3) 7 (41.2) 30 (65.2)
Discontinued due to AEs 0 1 (5.9) 1 (2.2)
Data are number (%) of patients. Cohort 2 included all patients aged 2–5 years
aIncludes all patients who did or did not participate in the vaccination substudy
bSAEs included febrile convulsions, tendon disorder, limb abscess, cellulitis and an overdose of mild intensity (administration of a higher abatacept dose due to
misclassification by weight tier)
cTreatment-related SAEs included a limb abscess that was severe in intensity and an overdose of mild intensity (administration of a higher abatacept dose due to
misclassification by weight tier)
AE adverse event, SAE serious adverse event
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Overall, paediatric patients with pJIA as young as 2 years
old who received 2–24months of SC abatacept treatment,
with the possible addition of MTX and low-dose cortico-
steroids, were able to maintain effective diphtheria and
tetanus vaccination protection without unexpected AEs.
These results show that SC abatacept does not prevent
the maintenance of protective antibody levels against
tetanus and diphtheria, even if the booster dose was not
administered recently.
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